Rockwell Medical, Inc. · NASDAQ:RMTI
Rockwell Medical — Investor Presentation (May 2025)
18 slides from Rockwell Medical's investor presentation, May 12, 2025
Slide 1: Investor Presentation
© ROCKWELL MEDICAL Investor Presentation May 12, 2025 RMT!
Slide 2: Forward-Looking Statements and Non-GAAP Measures
Forward-Looking Statements and Non-GAAP Measures Certain statements in this presentation may constitute “forward-looking statements” within the meaning of federal securities laws, including, but not limited to, Rockwell's expectations regarding revenue, profitability, financial position, 2024, 2025
Slide 3: Rockwell Medical At A Glance
Rockwell Medical At A Glance Healthcare company that develops, manufactures, commercializes, and distributes a portfolio of . hemodialysis products for dialysis providers worldwide. Business : Largest supplier of liquid bicarbonate hemodialysis concentrates in the U.S. Overview Second largest suppli
Slide 4: Executive Management Team
Executive Management Team President and Chief Executive Officer Dr. Mark Strobeck Aquilo ASSERTIO= fesk] ) SR One TOPAZ Zylam_ Chief Financial Officer Jesse Neri ARUVANT Spe s Symphony Health Zylax> Chief Legal Officer Megan Timmins Chief Corporate Affairs Officer Heather Hunter Chief Commercial Off
Slide 5: Corporate Strategy
Corporate Strategy gw te BF es Provide Customers with the Diversify our Customer Optimize our Business through Achieve Sustainable Highest Quality and Most Base and Product Portfolio Continued Manufacturing Profitability Reliable Products and Services Improvements 62025 Roctwell Medi ne QROCKWELL ME
Slide 6: Leading Manufacturer and Supplier of Concentrates
Leading Manufacturer and Supplier of Concentrates Hemodialysis is a Necessity for End Stage Renal Disease Patients Approximately 475,000 patients in the U.S. require in-center hemodialysis annually’). Each patient receives approximately 3 treatments per week, totaling ~150 in-clinic procedures per p
Slide 7: U.S. In-Center and Acute Care Hemodialysis Concentrates TAM
U.S. In-Center and Acute Care Hemodialysis Concentrates TAM ~4-6% CAGR driven primarily by increasing number of patients suffering from end-stage kidney disease 7 $560M 2024 2028 SOURCE: CAGR based on “Rockwell Medical: Concentrates Growth Strategy Report”, L.E.K. Consulting LLC (2022) ©2025 Rockwel
Slide 8: Sample of Dialysis Providers, Hospital Systems, Distributors that Rockwell Services
Sample of Dialysis Providers, Hospital Systems, Distributors that Rockwell Services Dialysis Providers Innovative Renal Care DGi.. Dialysis Clinic, Inc. Davita. Sanderling , Renal Services CONCERTO) SS” FRESENIUS Y MEDICAL CARE LO) ise Lower Manhattan DIALYSIS CENTER aQua DIALYSIS Hospital Systems U
Slide 9: Rockwell Distributes to 30+ Countries Worldwide
Rockwell Distributes to 30+ Countries Worldwide LE] Current Geographic Footprint | Current Expansion Opportunities ©2025 Rockwell Medical, Inc. (QROCKWELL MEDICAL
Slide 10: Key Drivers to Diversify our Customer Base and Product Portfolio
Key Drivers to Diversify our Customer Base and Product Portfolio Geographic Expansion Increase market share throughout the U.S. and internationally. Rockwell continues to secure commercial partnerships and seeks additional growth opportunities globally. At Home Treatments At home dialysis and transi
Slide 11: Product Portfolio now includes Bicarbonate Cartridge
Product Portfolio now includes Bicarbonate Cartridge Premium grade, single-use bicarbonate cartridges offered in two sizes: 720g and 900g. 510(k) approved. Single-use bicarbonate disposables represent an approximate $100 million market opportunity. One of the fastest growing segments within the hemo
Slide 12: Financials and Milestones
© ROCKWELL MEDICAL Financials and Milestones
Slide 13: First Quarter 2025 Financial Results
First Quarter 2025 Financial Results Three Months Ended March 31 (in Millions, Except Per Share Amounts) Net Sales 18.9 3.0 (1.4) 22.7 3.1 (1.3) Gross Profit Operating Income (Loss) Adjusted EBITDA (0.4) (0.04) (0.01) (0.5) (0.06) (0.02) Basic Net Income (Loss) per Share) $ $ $ $ $ $ Net Income (Los
Slide 14: 2025 Guidance
2025 Guidance = ! Ce] all Net Sales* Adjusted EBITDA Gross Margin $65.0M - $70.0M ($0.5)M - $0.5M 16% to 18% QROCKWELL MEDICAL
Slide 15: 2025 Projected Milestones
2025 Projected Milestones Achieve sustained profitability for FY’25 on an adjusted EBITDA basis. Grow concentrates business by adding new customers. Expand contracts and partnerships with existing customers. Continue to optimize our business through improved processes and expanded automated manufact
Slide 16: Why Invest in Rockwell Medical?
Why Invest in Rockwell Medical? Y Experienced Management Team Y Large and Growing Market Opportunity Y¥ Revenue-Generating Business ¥ Strong Financials Y Attractive Valuation 162025 Roctwell Median QROCKWELL MEDICAL
Slide 17: (© ROCKWELL Ss Z
(© ROCKWELL Ss Z MEDICAL QRockweue www.rockwellmed.com IR@rockwellmed.com
Slide 18: Reconciliation to GAAP Financial Measures
Reconciliation to GAAP Financial Measures Non-GAAP Financial Measures To supplement the Company's financial results presented on a U.S. generally accepted accounting principles ("GAAP") basis, the Company has included information about non-GAAP measures of EBITDA and adjusted EBITDA as useful operat